169 related articles for article (PubMed ID: 38278703)
1. Real-world Data and Evidence to support a switch in status from Prescription drug to Over the Counter drug as applied by the EMA, the US FDA, the MHRA, and the BfArM.
Kühler TC; Ateka A; Lassoued Z; Routhier FX; Mékary-Sawaya S
Clin Ther; 2024 Mar; 46(3):208-216. PubMed ID: 38278703
[TBL] [Abstract][Full Text] [Related]
2. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.
Mofid S; Bolislis WR; Kühler TC
Clin Ther; 2022 Feb; 44(2):306-322. PubMed ID: 35074209
[TBL] [Abstract][Full Text] [Related]
3. From prescription-only (Rx) to over-the-counter (OTC) status in Germany 2006-2015: pharmacological perspectives on regulatory decisions.
Barrenberg E; Garbe E
Eur J Clin Pharmacol; 2017 Jul; 73(7):901-910. PubMed ID: 28352949
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
5. A Detailed Analysis of the Past 20 Years of US FDA-Approved Prescription to Over-the-Counter Switches.
Fisher M; Rawal K
Ther Innov Regul Sci; 2023 Sep; 57(5):1074-1080. PubMed ID: 37357243
[TBL] [Abstract][Full Text] [Related]
6. Use of Real-world Data for New Drug Applications and Line Extensions.
Bolislis WR; Fay M; Kühler TC
Clin Ther; 2020 May; 42(5):926-938. PubMed ID: 32340916
[TBL] [Abstract][Full Text] [Related]
7. The effect on social welfare of a switch of second-generation antihistamines from prescription to over-the-counter status: a microeconomic analysis.
Shih YC; Prasad M; Luce BR
Clin Ther; 2002 Apr; 24(4):701-16. PubMed ID: 12017413
[TBL] [Abstract][Full Text] [Related]
8. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
9. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
[TBL] [Abstract][Full Text] [Related]
10. Switching omeprazole in Sweden and the United States.
Cohen J
Am J Ther; 2003; 10(5):370-6. PubMed ID: 12975722
[TBL] [Abstract][Full Text] [Related]
11. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
Vaghela S; Tanni KA; Banerjee G; Sikirica V
Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
[TBL] [Abstract][Full Text] [Related]
12. Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development.
Cohen J; Millier A; Karray S; Toumi M
J Med Econ; 2013; 16(6):835-44. PubMed ID: 23597040
[TBL] [Abstract][Full Text] [Related]
13. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
14. Widening consumer access to medicines through switching medicines to non-prescription: a six country comparison.
Gauld NJ; Kelly FS; Kurosawa N; Bryant LJ; Emmerton LM; Buetow SA
PLoS One; 2014; 9(9):e107726. PubMed ID: 25251434
[TBL] [Abstract][Full Text] [Related]
15. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
[TBL] [Abstract][Full Text] [Related]
16. The decision-making process of US Food and Drug Administration advisory committees on switches from prescription to over-the-counter status: a comparative case study.
Nguyen NT; Cook DM; Bero LA
Clin Ther; 2006 Aug; 28(8):1231-1243. PubMed ID: 16982301
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability.
Trygstad TK; Hansen RA; Wegner SE
J Manag Care Pharm; 2006 Mar; 12(2):108-20. PubMed ID: 16515369
[TBL] [Abstract][Full Text] [Related]
18. [The application of real-world evidence in drug regulatory decision-making].
Wicherski J; Haenisch B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Feb; 67(2):149-154. PubMed ID: 38214723
[TBL] [Abstract][Full Text] [Related]
19. Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information.
Lau C; Jamali F; Loebenberg R
J Pharm Pharm Sci; 2022; 25():227-236. PubMed ID: 35760071
[TBL] [Abstract][Full Text] [Related]
20. Rx-to-OTC switches: trends and factors underlying success.
Mahecha LA
Nat Rev Drug Discov; 2006 May; 5(5):380-5. PubMed ID: 16604099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
